Biocon Q4 Results: Cons PAT grows 31% YoY to Rs 313 crore, revenue surges 57%

May 23, 2023

The board has recommended a final dividend payout of Rs 1.50 per share. In FY23, Biocon’s revenue grew almost 37% to Rs 11,174 crore, while its net profit fell nearly 29% to Rs 463 crore. The biosimilars business segment more than doubled its year-on-year revenue to INR2,102 crore in Q4 2022.

More To Explore

Short-term dips seen as healthy realignments, not trend reversals: Deven Choksey

Deven Choksey of DRChoksey FinServ Pvt. Ltd. suggests the market is experiencing sector and stock rotations, with investors shifting from significantly appreciated stocks like Reliance

May 21, 2025

Market caution justified after sharp rally, investors should stay vigilant: Sudip Bandyopadhyay

Concerns are rising over the impending trade deal deadline between India and the United States, leading to market consolidation and profit booking. Inditrade Capital’s Sudip

May 21, 2025

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003